ConcertAI has been on a deal-making spree this year to secure its own pharma partnerships inside and outside of immuno-oncology. Since March, the company has signed on Bristol Myers Squibb [51, Pfizer [61, and Astellas [11 to use its Al platform; dollar figures weren’t disclosed with the partnerships, but they are generally leveraging ConcertAI's access to the American Society for Clinical Oncology (ASCO) CancerlinQ Discovery database, which links EHRs from its extensive pool of cancer patients.